Loading page
What we know about this company
A dated company review is availableOklo Inc.
OKLO hit a genuine milestone: first criticality at Groves in ~11 months is the fastest for any privately funded full-scale reactor, and first revenue ($1.21M) has arrived.
TickerYou is watching this company, but we are not currently recommending it. An earlier full review was positive 6/10, but that view is historical.
$36.22
last session
Price only · no current Idea
Quarterly results window begins in 50 days · Nov 1–30 · Estimated range
This came from an earlier review. It is useful background, not a current Idea.
Oklo is trying to build small nuclear power plants and sell the electricity directly to big customers — mainly the giant data centers that run artificial intelligence for companies like Meta. It doesn't really make money yet: last quarter it took in about $1.2 million and lost about $48 million. In August 2026 it hit a big milestone — its Groves reactor in Texas 'went critical,' meaning a self-sustaining nuclear reaction started, built in under a year. But Groves makes medical and industrial isotopes, not commercial electricity. Its first plant that actually sells power, in Idaho, isn't due until 2028, and the big Meta project in Ohio not until 2030. The one thing that has to go right: it must win its safety license from nuclear regulators and build on time and on budget. The one thing that could go wrong: it keeps paying for everything by selling new shares, so your ownership shrinks — and any delay hits a stock already priced for success.
Loading company numbers
Loading latest quarterly results
Loading ownership and market expectations
Supplemental SEC filing context loads independently from the company evidence above.
Checking the newest complete filings from the large investors we follow. The rest of this page is ready while these delayed reports load.
TickerYou is checking this company, but no active investment Idea is open.
That review was positive with 6/10 research strength. It is history, not a current Idea.
Read the newest company check below. New facts can update the research, but watching a company does not turn it into a recommendation.
OKLO hit a genuine milestone: first criticality at Groves in ~11 months is the fastest for any privately funded full-scale reactor, and first revenue ($1.21M) has arrived.
OKLO hit a genuine milestone: first criticality at Groves in ~11 months is the fastest for any privately funded full-scale reactor, and first revenue ($1.21M) has arrived. But $48.5M quarterly net losses widening quarter-over-quarter and capex ramping to $400–500M in 2026 alone make this a long-dated, high-conviction-required position. $3B cash is adequate runway. Story intact — conviction depends on regulatory progress and power purchase agreements materializing on schedule.
Loading research history
Earlier company review · Record saved Aug 12, 2026 · check date unavailable. The original research wording and date checks stay available inside.
These events and risks came from an earlier company review. There is no current Idea.
An event can change what investors believe. A risk shows how our research could be wrong. The countdown is to the start of a window, not a promised event day.
Watch for a company announcement that confirms, narrows, moves, or cancels this window.
An older company check saved this date without enough source detail. We therefore show the date as not confirmed.
OKLO hit a genuine milestone: first criticality at Groves in ~11 months is the fastest for any privately funded full-scale reactor, and first revenue ($1.21M) has arrived.
A company check updates what we know. It does not by itself turn this company into a current opportunity.
1 older quarterly-results date is hidden because a newer company check is shown above.
Computed by TickerYou from 1254 completed daily closing sessions supplied by Yahoo Finance, through Sep 10, 2026. The Sep 11, 2026 quote-session candle was excluded because a delayed feed cannot prove it was final. No company fundamentals enter this reading.
The price has been trending down across both the medium and longer term.
Price movement can help with timing and can warn when the market disagrees with our Idea. It does not tell us what the business is worth.
Watch whether the close can recover above the 50-session average at $43.49; the 200-session average at $64.04 is the slower reference.
Last closing price
$39.88
Sep 10, 2026
Average price over 20 trading days
$41.82
Close is 4.6% below this average
Average price over 50 trading days
$43.49
Close is 8.3% below this average
Average price over 200 trading days
$64.04
Close is 37.7% below this average
Recent price speed
44.7 · balanced
A 14-day speed reading; lower than 30 is low and higher than 70 is high
Is the trend speeding up?
Above signal
Shows whether the shorter trend is pulling ahead of or behind the longer one
The moving averages are simple averages over exactly 20, 50, and 200 daily trading sessions. RSI uses Wilder's 14-session smoothing; a flat series is neutral at 50. MACD uses 12- and 26-session exponential averages with a 9-session signal. A window is never shortened when history is missing. Every comparison uses the final dated daily close—not an intraday quote—so all figures share one observation boundary. A candle dated to an active delayed-quote session is excluded because it may still be changing. These are trend and momentum references, not a Buy/Sell score.
We keep the original wording so readers can check the record. Any figures below belong to that older review and are not current guidance.
Long, but conviction downgraded to 6/10 on a 1-year horizon. Groves criticality is a real technical win and the pipeline is genuine, yet it de-risks the isotope and technology story more than the commercial-power revenue that justifies an ~$8.5B valuation. Severe ongoing dilution ($1.9B issued in 2026), no commercial electricity until 2028, and analyst target cuts after Q2 argue for owning it small as a very-speculative long-term option, not a high-conviction core position.
TickerYou has not saved a quarterly report for this company yet. We show nothing instead of guessing.
We do not have enough filed quarterly numbers to compare this company yet. We leave the section blank instead of guessing.
Three checks use SEC filings alone. The net-buyback check requires matching stated filing and quote currencies, a compatible single-ticker SEC share-unit receipt, and a dated provider quote; its row explains any refusal. One dated deep-review judgement is marked researched; missing checks are excluded, never treated as zero.
A score requires both core checks — what the share count did and pay in stock versus revenue — plus at least one other established check. Missing core checks: what the share count did; pay in stock, vs revenue.
A company can grow while each shareholder owns a smaller slice. Share issuance and stock pay can offset part of the business gain.
Establish the missing core checks first; other unestablished checks: buybacks net of new stock sold; room left under the charter.
could not be checked just now
could not be checked just now
neither side of the share ledger is tagged in this filer’s feed
The deep review’s dated judgement (published Aug 12, 2026; evidence cutoff unavailable): how much of a 1% ownership slice at that review could survive through its horizon.
could not be checked just now
review saved Aug 12, 2026 · check date unavailable
The founders, Jacob and Caroline DeWitte, still own about 12% — roughly 21 million shares — so management has real skin in the game, though the CEO has been selling small pre-planned amounts. The bigger issue is how Oklo pays for itself: it prints and sells new shares. In the first half of 2026 it sold about 23 million new shares for $1.9 billion, and the share count rose more than 15% to about 186 million by early August. A fresh $1 billion share-selling program is still open, and staff are paid heavily in stock. So every existing owner's slice keeps shrinking. That cash buys runway to 2028, but the price is constant dilution — if you own a piece today, you will almost certainly own less of it a year from now.
1M
3M
6M
1Y
Every figure comes from an SEC filing and carries the day it was measured. Nothing here is estimated.
A year-over-year share-count conclusion is not established: could not be checked just now.
Without two comparable filed counts, the app cannot say whether existing owners gained or lost percentage ownership.
Watch for two comparable filing cover pages before interpreting dilution or ownership-slice change.
Total share count — not known yet
could not be checked just now
The request for this filer's cover-page share count did not reach the SEC — a rate limit, a server error, or a dropped connection on our side. That is a failure of ours and carries no information about the company: it is NOT evidence that the filer does not report the figure. The number is withheld rather than guessed, and returns on the next successful load.
No bar is drawn: with no total share count there is nothing to draw a proportion of.
could not be checked just now
Not researched yet. Release dates, tranche sizes, the shares issued at IPO and the insider breakdown are prose in the prospectus and in 8-Ks, with no XBRL tag to read them from. They appear here once TickerYou research can quote the source clause behind each figure—never estimated in the meantime.
Append-only company checks, newest evidence first. Evidence dates come from frozen research cutoffs; older rows without a cutoff are labelled by publication time instead. Multiple checks are preserved, never silently merged into one conclusion.
OKLO hit a genuine milestone: first criticality at Groves in ~11 months is the fastest for any privately funded full-scale reactor, and first revenue ($1.21M) has arrived. But $48.5M quarterly net losses widening quarter-over-quarter and capex ramping to $400–500M in 2026 alone make this a long-dated, high-conviction-required position. $3B cash is adequate runway. Story intact — conviction depends on regulatory progress and power purchase agreements materializing on schedule.
Published Aug 12, 2026 · 3 recorded assessments
Oklo delivered its two most consequential milestones yet in a single week: Groves first criticality in under 11 months (claimed fastest private U.S. reactor build from greenfield) and its first reported revenue. The loss is widening with construction acceleration, but a $3B cash position makes runway irrelevant for years. Aurora-INL site excavation is nearly complete with a 2028 start target; Aurora-Ohio is early 2030. Commercial power revenue is still distant and the stock is priced for optimistic execution, but the Groves milestone meaningfully de-risks that execution path. The key open question is whether the construction model that worked for a small isotope reactor scales to commercial power units.
First criticality in approximately 11 months from groundbreaking is the most significant operational milestone in Oklo's history; it de-risks the construction timeline for future Aurora units and provides real construction and operational experience the company previously lacked.
Accelerated spending confirms commitment to the deployment timeline but means losses are widening — $48.5M net loss vs $33.1M in Q1 2026. $3B in liquidity provides roughly 5–6 years of runway at current burn, limiting near-term dilution risk.
source ↗Operationally and competitively transformative: Oklo now holds real fast-spectrum criticality data, removes regulatory and execution risk from the construction model, and claims potentially the fastest privately funded reactor build in U.S. history.
source ↗First reported revenue and confirmation of a $3B cash runway make this earnings call materially different from prior quarters. Wider losses reflect accelerated construction spend, not deterioration of the business model.
source ↗First criticality at the Groves facility on August 5-6, 2026 is the single most important milestone Oklo could have hit at this stage — it proves the reactor design works at full scale under real-world DOE oversight, and management's claim of record speed adds credibility. The $3B liquidity buffer insulates against any delays in the commercial deployment curve. The Meta 1.2GW prepayment agreement provides contracted demand. Key remaining risks: regulatory license for power generation, NRC operating permit, and the gap from criticality to commercial grid power delivery. Conviction strengthened materially this week.
First criticality converts Oklo from a paper reactor company to an operational nuclear power producer; management claims it is the fastest greenfield-to-criticality in history for a full-scale privately funded US reactor (~11 months). This fundamentally de-risks the commercial deployment and revenue timeline.
source ↗Q2 results confirm $3B cash runway and no near-term dilution risk; management presented an accelerated deployment timeline underpinned by the Meta Platforms prepayment agreement for 1.2GW campus in Ohio.
source ↗Price movement reaction; not a change in fundamentals.
source ↗Oklo's Groves criticality is a genuine inflection — fastest greenfield-to-criticality in US nuclear history, achieved on private land under the DOE Pilot Program, and it meaningfully compresses the perceived timeline risk on the commercial Aurora reactor. The $3B cash position removes any near-term funding concern. That said, zero revenue today, multi-year path to first commercial operation, and a CEO selling shares systematically every month are structural concerns at ~$45/share. Investors are paying pre-revenue biotech-style multiples on a nuclear company whose first commercial powerhouse has no confirmed revenue contract yet. The 3m outlook depends heavily on whether the market continues to assign option value to the criticality milestone or begins demanding revenue evidence. At a 1y horizon, the catalysts are: (1) first commercial power purchase agreement signed, (2) NRC design certification progress for Aurora, and (3) possible DOE advanced reactor program awards. Without at least one of those, the valuation premium is hard to sustain.
First-ever privately funded, privately sited US reactor to achieve criticality under DOE's Reactor Pilot Program — the fastest greenfield-to-criticality transition in US nuclear history. Materially de-risks Oklo's commercial Aurora powerhouse deployment timeline and proves out the NRC licensing and construction pathway at speed.
source ↗Confirms $3B cash runway (no near-term dilution risk), operating losses as expected for pre-revenue nuclear developer, and management framing of accelerated deployment timeline; the stock reaction reflects market treating the criticality milestone as fundamental validation.
source ↗Complete SEC 13F filings only. These delayed reports show filed share amounts, not a manager’s full portfolio, intent, or a proven trade.
3 of 14 recent complete filings report ordinary shares. Compared with the prior report: 2 with more shares and 1 with fewer shares.
A large, repeated position can support a research story, but these filings arrive late and do not show an investor’s full portfolio or reason for owning the stock.
Look for the same investor to keep a meaningful position across several reports.
No numeric score or recommendation is made from these delayed filings. They are one piece of background evidence, not a buy or sell signal.
14 current complete filings of 16 tracked managers. 2 investors have only an older filing and are left out of this current view. Current holding dates span Mar 31, 2026 to Jun 30, 2026.
OKLO is 0.13% of ARK Investment Management's disclosed portfolio ($19.48 M). Holdings as of Jun 30, 2026. Reported in all 6 quarters we can see.
OKLO is 0.01% of Bridgewater Associates's disclosed portfolio ($2.94 M). Holdings as of Jun 30, 2026. Reported in 4 consecutive quarters.
OKLO is 0.00% of Citadel Advisors's disclosed portfolio ($1.48 M). Holdings as of Jun 30, 2026. Reported in all 2 quarters we can see.
Market-neutral / multi-strategy: Citadel often reports shares, calls, and puts at the same time. These rows show reported exposure, not a simple bullish or bearish bet.
Citadel Advisors (Ken Griffin) reports a PUT option ($102.42 M). The filing does not prove whether it is a bet or a hedge, so options never count as ordinary shares above.
Citadel Advisors (Ken Griffin) reports a CALL option ($255.32 M). The filing does not prove whether it is a bet or a hedge, so options never count as ordinary shares above.
2 newly or higher reported, 1 lower reported. Reported amounts only; corporate actions are not normalized.
Reported by 3 of 14 managers with a current filing; at least 0.5% of disclosed 13F value for 0.
Largest reported position: ARK Investment Management (Cathie Wood) at 0.13% of disclosed 13F value ($19.48 M).
Across 6 quarters of stored filings: 9 newly or higher comparisons, 6 lower or absent, 0 unchanged, across 5 managers. Corporate actions are not normalized.
No numeric score is shown: filing comparisons are not adjusted for splits or other corporate actions, so reported changes cannot be treated as trades.
13Fs can arrive up to 45 days after quarter end. They omit short positions, cash, and securities outside the SEC's 13(f) list. Higher, lower, new, and absent describe filed share amounts, not proven purchases or sales; splits and other corporate actions are not normalized. This is context for a thesis, never a call by itself.